Gemcitabine immunoassay
AssigneeSaladax Biomedical Inc.
InventorsSalvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
Life of this patent
Estimating the term…
Abstract
The present invention comprises novel analogs of gemcitabine and novel gemcitabine immunogens teased out of, i.e., derived from, the 5′-hydroxy position of gemcitabine. The invention also comprises unique monoclonal antibodies generated using gemcitabine linked immunogens as well as unique conjugates and tracers which antibodies, conjugates, and tracers are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids.
Claims28
An antibody which binds selectively to gemcitabine and does not substantially bind to 2′,2′-difluoro-2′-deoxyuridine and tetrahydrouridine.
The antibody wherein said antibody is a monoclonal antibody.
A compound of the formula:
- wherein B is —CH2— or
- Y is an organic spacing Stoup;
- X is a functional group capable of binding to said carrier through said amino or thiol group;
- and
- p is an integer from 0 to 1
- X is a functional group capable of binding to a thiol or an amino group;
- and B is —CH2— or
- or salts thereof.
A conjugate of a carrier having a thiol or amine group with a compound of the formula:
- wherein B is —CH2— or
- Y is an organic spacing group;
- X is a functional group capable of binding to said carrier through said amino or thiol group;
- and
- p is an integer from 0 to 1
- or salts thereof:
A kit for determining the presence of gemcitabine in a patient sample comprising reagents in separate containers, one of the reagents being a conjugate of a carrier containing a functional amino or thiol group with a compound selected from the groups consisting of compounds of the formula:
- wherein B is —CH2— or
- Y is an organic spacing group;
- X is a functional group capable of binding to said carrier through said amino or thiol group;
- and
- p is an integer from 0 to 1
- or salts thereof;
- and the second container containing an antibody substantially selectively reactive with gemcitabine and not substantially cross-reactive to 2,2′-difluoro-2′-deoxyuridine and tetrahydrouridine
The kit of claim 27, wherein said carrier has a reactive terminal functional thiol group and X is a terminal functional group capable of binding to said thiol group.
The kit wherein X is
Dependencies are inferred from the claim text.